Cingulate Inc. Common Stock CING
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T03:04:01.145Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.211326716Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T03:04:00.787239+00:00
Cingulate Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.26 | 149.2% | 34.5% | |||
| 25Δ | 3.49 | 140.8% | 30.6% | |||
| 30Δ | 3.71 | 132.4% | 26.8% | |||
| 35Δ | 3.94 | 124.0% | 22.9% | |||
| 40Δ | 4.16 | 115.5% | 19.1% | |||
| 45Δ | 4.39 | 107.1% | 15.2% | |||
| 50Δ | 4.61 | 98.7% | 11.3% | |||
| 55Δ | 4.84 | 90.3% | 7.5% | |||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | 3.62 | 281.6% | 11.1% | |||
| 75Δ | 3.31 | 315.3% | 10.3% | |||
| 80Δ | 2.99 | 349.1% | 9.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.26
- IV
- 149.2%
- B/E move
- 34.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.49
- IV
- 140.8%
- B/E move
- 30.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.71
- IV
- 132.4%
- B/E move
- 26.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.94
- IV
- 124.0%
- B/E move
- 22.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.16
- IV
- 115.5%
- B/E move
- 19.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.39
- IV
- 107.1%
- B/E move
- 15.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.61
- IV
- 98.7%
- B/E move
- 11.3%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.84
- IV
- 90.3%
- B/E move
- 7.5%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.62
- IV
- 281.6%
- B/E move
- 11.1%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 3.31
- IV
- 315.3%
- B/E move
- 10.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.99
- IV
- 349.1%
- B/E move
- 9.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 160.23% |
Biotechnology
CLDX
Description unavailable
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →CMPX
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The…
More →CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe…
More →COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge,…
More →CORT
Description unavailable
More →